Medivir AB (OSTO:MVIR) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:MVIR Medivir AB OSTO:MVIR
40 GF Score
Price kr1.90
GF Value kr1.00
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Medivir AB Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

OSTO:MVIR
40GF Score
Medivir AB OSTO:MVIR
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Medivir AB (OSTO:MVIR) Overvalued in 2026?

Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued. The current stock price of kr1.90 is trading 90% above its estimated GF Value™ of kr1.00. GuruFocus considers Medivir AB to be Significantly Overvalued.

Key valuation signals for OSTO:MVIR:

  • Dividends Received:
  • GF Value™: kr1.00 vs. price of kr1.90 (90% above fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the OSTO:MVIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medivir AB Business Description

Other Exchanges MVIRs:UK0GP7:UKMVR0:Germany
Address Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
40GF Score

Get the complete analysis for OSTO:MVIR

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.90
Price
kr1.00
GF Value